Varicella Vaccination With Pulmicort
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: budesonide (Drug); varicella zoster virus (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Bertill Andersson, Study Director, Affiliation: AstraZeneca employee
Summary
A study to determine whether treatment with Pulmicort in children has any effect on the
varicella vaccine
Clinical Details
Official title: Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy
Study design: Treatment, Non-Randomized, Open Label, Parallel Assignment, Efficacy Study
Primary outcome: Seroconversion level
Eligibility
Minimum age: 10 Months.
Maximum age: 8 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Children between the age of 10 months and 8 years,
- have asthma or shown recent signs suggesting asthma,
- have a parent or guardian willing to comply with study requirements
Exclusion Criteria:
- Varicella zoster immune globulin (VZIG) within 5 months prior to immunization,
- Previous varicella immunization,
- an immunization or allergy immunotherapy 4 weeks prior to immunization,
- Severe asthma,
- have another persistent lung disease,
- have a planned hospitalization for the duration of study
Locations and Contacts
Additional Information
Starting date: October 2001
Ending date: June 2004
Last updated: March 21, 2008
|
